Cited by 486Liver Disease Diagnosis and TreatmentInflammasome and immune disordersLiver physiology and pathology

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

NLRP3 inflammasome activation is required for fibrosis development in NAFLD

Open access

Wree, Alexander, McGeough, Matthew D., Peña, Carla A., Schlattjan, Martin, Li, Hongying, Inzaugarat, Maria Eugenia, Messer, Karen, Canbay, Ali, Hoffman, Hal M., Feldstein, Ariel E.·2014·Journal of Molecular Medicine

DOI 10.1007/s00109-014-1170-1PMC PMC4349416

Open this paper in CoChat — free account Open PDF

Abstract

NLR inflammasomes, caspase 1 activation platforms critical for processing key pro-inflammatory cytokines, have been implicated in the development of nonalcoholic fatty liver disease (NAFLD). As the direct role of the NLRP3 inflammasome remains unclear, we tested effects of persistent NLRP3 activation as a contributor to NAFLD development and, in particular, as a modulator of progression from benign hepatic steatosis to steatohepatitis during diet-induced NAFLD. Gain of function tamoxifen-inducible Nlrp3 knock-in mice allowing for in vivo temporal control of NLRP3 activation and loss of function Nlrp3 knockout mice were placed on short-term choline-deficient amino acid-defined (CDAA) diet, to induce isolated hepatic steatosis or long-term CDAA exposure, to induce severe steatohepatitis and fibrosis, respectively. Expression of NLRP3 associated proteins was assessed in liver biopsies of a well-characterized group of patients with the full spectrum of NAFLD. Nlrp3(-/-) mice were protected from long-term feeding CDAA-induced hepatomegaly, liver injury, and infiltration of activated macrophages. More importantly, Nlrp3(-/-) mice showed marked protection from CDAA-induced liver fibrosis. After 4 weeks on CDAA diet, wild-type (WT) animals showed isolated hepatic steatosis while Nlrp3 knock-in mice showed severe liver inflammation, with increased infiltration of activated macrophages and early signs of liver fibrosis. In the liver samples of patients with NAFLD, inflammasome components were significantly increased in those patients with nonalcoholic steatohepatitis (NASH) when compared to those with non-NASH NAFLD with mRNA levels of pro-IL1 beta correlated to levels of COL1A1. Our study uncovers a crucial role for the NLRP3 inflammasome in the development of NAFLD. These findings may lead to novel therapeutic strategies aimed at halting the progression of hepatic steatosis to the more severe forms of this disease. Key message: Mice with NLRP3 inflammasome loss of function are protected from diet-induced steatohepatitis. NLRP3 inflammasome gain of function leads to early and severe onset of diet-induced steatohepatitis in mice. Patients with severe NAFLD exhibit increased levels of NLRP3 inflammasome components and levels of pro-IL1β mRNA correlate with the expression of COL1A1.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00109-014-1170-1

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791
Pattern Recognition Receptors and Inflammation
Takeuchi, O., & Akira, S. (2010) · Cell · doi:10.1016/j.cell.2010.01.022 · Cited by 8,895
The Inflammasome
Martinon, F., Burns, K., & Tschopp, J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00599-3 · Cited by 6,066
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults
Vernon, G. C., Baranova, A. V., & Younossi, Z. M. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04724.x · Cited by 3,116
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Self-citation
The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
Vandanmagsar, B., Youm, Y.-H., Ravussin, A., Galgani, J. E., Stadler, K., Mynatt, R. L., Ravussin, E., Stephens, J. M., & Dixit, V. D. (2011) · Nature Medicine · doi:10.1038/nm.2279 · Cited by 2,655
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Self-citation
Fatty acid–induced NLRP3-ASC inflammasome activation interferes with insulin signaling
Wen, H., Gris, D., Lei, Y., Jha, S., Zhang, L., Huang, M. T.-H., Brickey, W. J., & Ting, J. P.-Y. (2011) · Nature Immunology · doi:10.1038/ni.2022 · Cited by 1,698

Show all 43 references

Sorted by citations

Items 401–485 of 485

Species differences of fatty liver diseases: comparisons between human and feline
Ling, L., Li, R., Xu, M., Zhou, J., Hu, M., Zhang, X., & Zhang, X.-J. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00014.2024 · Cited by 5
Update in non-alcoholic fatty liver disease management: role of sodium-glucose cotransporter 2 inhibitors
Zambrano-Vásquez, O. R., Cortés-Camacho, F., Castañeda‐Sánchez, J. I., Aréchaga-Ocampo, E., Valle-Velázquez, E., Cabrera-Angeles, J. C., Sánchez-Gloria, J. L., Sánchez‐Muñoz, F., Arellano-Buendía, A. S., Sánchez‐Lozada, L. G., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123638 · Cited by 5
Metabolic characteristics and renal dysfunction in 65 patients with tophi prior to gout
Lu, C.-C., Wu, S., Chung, W., Lin, L.-H., Hung, T.-W., & Yeh, C. (2017) · Clinical Rheumatology · doi:10.1007/s10067-017-3663-0 · Cited by 4
Intestinal microbiota participates in nonalcoholic fatty liver disease progression by affecting intestinal homeostasis
Zhang, Y., Li, J., Zhang, Y., & Wang, Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i23.6654 · Cited by 4
Long non-coding RNA-EN_181 potentially contributes to the protective effects of N-acetylcysteine against non-alcoholic fatty liver disease in mice
Yang, W., Guo, R., Pi, A., Ding, Q., Hao, L., Song, Q., Chen, L., Dou, X., Na, L., & Li, S. (2022) · British Journal Of Nutrition · doi:10.1017/s0007114522001829 · Cited by 4
Heterogeneous population of macrophages in the development of non-alcoholic fatty liver disease
Cho, Y. E., Kwon, Y. S., & Hwang, S. (2022) · Liver Research · doi:10.1016/j.livres.2022.06.001 · Cited by 6
Non-alcoholic fatty liver disease as an independent factor of cardiometabolic risk of cardiovascular diseases
Garbuzenko, D. V., & Belov, D. V. (2021) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-194-10-22-34 · Cited by 4
Regulated necrosis at the crossroads of liver inflammation and cancer development
Vucur, M., Kondylis, V., Brož, P., & Luedde, T. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01147-8 · Cited by 6
Dietary polyphenols targeting NLRP3 inflammasome in obesity and metabolic disorders: a review on experimental and computational evidence
Subaş, T., Çetinkaya, S., Şirin, S., Baser, T., & Süntar, I. P. (2026) · International Journal of Food Sciences and Nutrition · doi:10.1080/09637486.2026.2625829 · Cited by 3
Lipid metabolism-MAFLD crosstalk: mechanisms and therapy
Li, B., Piao, S., Fu, Y., Fu, Q., Qin, P., Kong, W. K., Ma, Y., Zhang, Z., Fang, X., & Hu, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1785178 · Cited by 5
Exploring dietary flavonoid and gut microbiota interactions: Therapeutic insights into metabolic syndrome management
Saikia, L., Kalita, P., Das, B. K., Law, D., Talukdar, N. C., & Dutta, P. P. (2026) · Food and Humanity · doi:10.1016/j.foohum.2026.101138 · Cited by 3
iTRAQ-based quantitative proteomics analysis of the effect of ACT001 on non-alcoholic steatohepatitis in mice
Zhou, H., Niu, B., Wu, X., Chu, W., Zhou, Y., Chen, Z., Mi, Y., Liu, Y., & Li, P. (2023) · Scientific Reports · doi:10.1038/s41598-023-38448-4 · Cited by 3
Gut Microbiome and Liver Diseases from the Perspective of 3PM: The Predictive, Preventive, and Personalized Medicine
Skladaný, Ľ., Koller, T., Kukla, M., & Šoltýs, K. (2023) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-031-34884-6_9 · Cited by 3
Auranofin attenuates Schistosoma mansoni egg-induced liver granuloma and fibrosis in mice
Atia, A. F., HUSSIEN, N. M. A., Sweed, D., Sweed, E. M., & Abokhalil, N. (2023) · Journal of Helminthology · doi:10.1017/s0022149x23000792 · Cited by 3
Unveiling the nexus: pyroptosis and its crucial implications in liver diseases
Miao, Z., Zhang, X., Xu, Y., Liu, Y., & Yang, Q. F. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05147-1 · Cited by 3
Ameliorating effects of melatonin on high-fat diet induced non-alcoholic fatty liver diseases and their associated pathologies: A comprehensive review
Ghosh, S., Khatoon, R., Sarkar, S., & Bandyopadhyay, D. (2023) · Melatonin Research · doi:10.32794/mr112500138 · Cited by 2
Chronic hepatitis С and non-alcoholic fatty liver disease. Main aspects of pathogenesis
Zhdanov, K. V., Karyakin, S. S., Kozlov, K. V., Gusev, D. A., Sukachev, V. S., Saulevich, A. V., Yaremenko, M. V., Kizhlo, S., Shakhmanov, D. М., Lobzin, D. Y., et al. (2018) · Bulletin of the Russian Military Medical Academy · doi:10.17816/brmma12326 · Cited by 3
Insulin resistance and liver histopathology in metabolically unhealthy subjects do not correlate with the hepatic abundance of NLRP3 inflammasome nor circulating IL-1β levels
Quezada, N., Valencia, I., Torres, J., Maturana, G., Jaime Cerda, L., Arab, J. P., Fuentes, J. J., Pinto, C., Turiel, D., & Cortés, V. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001975 · Cited by 4
CDK5RAP3 Deficiency Is Associated with Hepatic Inflammation and Increased Expression of NLRP3 Inflammasome Components
Chen, X., Huang, Y., Wu, Y., Sheng, L., Yan, H., Chen, F., Li, F., Ketema, H., & Cai, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13082030 · Cited by 2
Unveiling MASH: a comprehensive review highlighting experimental insights, molecular pathogenesis, and therapeutic approaches
Ezz-Eldin, Y. M., Azouz, A. A., Khalaf, M. M., & Ewees, M. G. (2026) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2026.2638333 · Cited by 2
A patent review of NLRP3 inhibitors for inflammatory diseases (2023-present)
Namme, J. N., Xu, Y., McClendon, E., Zhang, C. M., & Zhang, S. (2026) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2026.2656161 · Cited by 2
Traditional Chinese Medicine Modulation of the Gut–Liver Axis: From Barrier Disruption to Inflammasome Activation in MASLD/MASH
Ren, L., He, Q., Hu, Z., Jin, J., & 陶飞宝 (2026) · Journal of Visualized Experiments · doi:10.3791/70259 · Cited by 2
The NLRP3 inflammasome in metabolic dysfunction-associated steatotic liver disease: role and advances in therapeutic targeting
Wei, S., He, Y., Luo, C., & He, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1924392 · Cited by 4
Role of Renin-Angiotensin System in the Pathogenesis and Progression of Non-alcoholic Fatty Liver
Badr, A. M., Sherif, I. O., Mahran, Y. F., & Attia, H. (2023) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-23621-1_10 · Cited by 2
Co-exposure to different bacterial species’ lipopolysaccharides with the NASH diet exacerbates NASH and liver fibrosis progression in mice
Lee, Y.-P., Chiu, C.-C., Chang, Y., Chen, Y., Wu, W., Wu, M., & Chuang, H.-L. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102470 · Cited by 2
Diabetic Cardiomyopathy Uncovered: Transcriptomics, NLRP3, and Carvedilol Mechanisms
Abudoureyimu, A., Aihaiti, A., Abudoujilili, N., Tuergong, M., Adili, G., Maimaiti, M., Mohetaer, D., & Maiamaitishawuti, Y. (2024) · Journal of Diabetes Research · doi:10.1155/2024/9378405 · Cited by 2
HFD Exacerbates Hepatic Lipid Metabolism Disorders After Cholecystectomy by Regulating the Bile Acid and Neutrophil Recruitment
Xu, Y., Zhang, F., Ke, Z., Lin, Y., Zhang, Y., Liu, Y., Zhang, Y. Y., Xu, J., & Liu, Y. (2025) · Liver International · doi:10.1111/liv.70130 · Cited by 2
Hepatocyte Death in Liver Inflammation, Fibrosis, and Tumorigenesis
Hsin, I., & Seki, E. (2017) · Springer eBooks · doi:10.1007/978-3-319-53774-0_10 · Cited by 2
Inflammasome-induced inflammation and fibrosis in liver
Kaufmann, B. K., Kim, A. D., & Feldstein, A. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91802-2.00017-7 · Cited by 2
Self-citation
Comparative efficacy of febuxostat and vitamin E in the management of MASLD: Insights from a randomized parallel clinical study
El-sheikh, H. M., El-Haggar, S. M., Badawi, R., & Habba, E. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177735 · Cited by 1
Interleukin-18 binding protein protects against metabolic steatohepatitis
Somm, E., Jo, Y., Perroud, E., Ino, F., Lindner, K., Kang, B. E., Veyrat‐Durebex, C., Bontems, F., Visentin, F., Fauteux‐Daniel, S., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000840 · Cited by 1
Phytochemicals as promising therapeutic approaches for inflammasomes-related metabolic disorders
Khuspe, P. R., Pagar, R. R., Pardeshi, S. R., Meshram, P. D., Gholap, A. D., Dhole, S. J., Kole, E. B., & Naik, J. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-31698-2.00022-9 · Cited by 1
Myeloid HDAC7 drives liver inflammation and systemic glucose dysregulation during diet‐induced obesity
Wang, Y., Ramnath, D., Gupta, K. D., Prakrithi, P., Bisht, K., Miller, G. C., Xiong, Z., Wan, Y., Tejo, E. N., Curson, J. E. B., et al. (2026) · Clinical & Translational Immunology · doi:10.1002/cti2.70100 · Cited by 1
[Adeno-associated virus-mediated hepatocyte-specific NDUFA13 overexpression protects against CCl4-induced liver fibrosis in mice by inhibiting hepatic NLRP3 activation].
Xu, X., Feng, J., Luo, Y., He, X., Zang, J., & Huang, D. (2024) · PubMed · doi:10.12122/j.issn.1673-4254.2024.02.01 · Cited by 1
Cholesterol, stearic and palmitic acids in the liver in nonalcoholic steatohepatitis of different severity according to the data of highly effective liquid chromatography-mass spectrometry
Tumanskiy, V. A., Фень, С. В., & Varinskyi, B. A. (2016) · Pathologia · doi:10.14739/2310-1237.2016.3.87485 · Cited by 1
Role of Inflammasomes in the Development of Gastrointestinal Diseases
Kanak, M. A., Shindo, Y., SaiKumar, P., & Naziruddin, B. (2018) · Experientia supplementum · doi:10.1007/978-3-319-89390-7_10 · Cited by 1
Angeborene Immunität und Adipositas – Die Rolle der Nod-like-Rezeptoren (NLR)
Mirza, N., Bauer, S., & Kufer, T. A. (2019) · Aktuelle Ernährungsmedizin · doi:10.1055/a-0918-5630 · Cited by 1
Beneficial Effects of Ketogenic Diet on Nonalcoholic Steatohepatitis in Obese Mice Model
Charlot, A., Charles, A., Georg, I., Goupilleau, F., Debrut, L., Pizzimenti, M., Mallard, J., Pagano, A. F., Gény, B., & Zoll, J. (2022) · International Electronic Conference on Nutrients (IECN) · doi:10.3390/iecn2022-12368 · Cited by 3
From fatty liver to nonalcoholic steatohepatitis with fibrosis
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00013-5 · Cited by 1
Lipotoxicity in Non-alcoholic Fatty Liver Disease: Mechanisms and Prevention in Experimental Models
Geng, Y. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.130260314 · Cited by 2
Single-Cell Transcriptomic Analysis of Livers During NLRP3 Inflammasome Activation Reveals a Novel Immune NichePreprint
Calcagno, D. M., Chu, A., Gaul, S., Taghdiri, N., Toomu, A., Leszczynska, A., Kaufmann, B. K., Wree, A., Geisler, L. J., Hoffman, H. M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437725 · Cited by 1
Self-citation
Reply to: Comments on “Air Space Distension Precedes Spontaneous Fibrotic Remodeling and Impaired Cholesterol Metabolism in the Absence of Surfactant Protein C”
López-Rodríguez, E., & Ochs, M. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0158le · Cited by 1
CDK5RAP3 Deficiency Exacerbates Hepatic Inflammation via NLRP3 Inflammasome-Mediated Pyroptosis and Apoptotic CrosstalkPreprint
Chen, X., Huang, Y., Wu, Y., Sheng, L., Yan, H., Chen, F., Li, F., Ketema, H., & Cai, Y. (2025) · Preprints.org · doi:10.20944/preprints202506.2315.v1 · Cited by 1
Gut microbiota-derived indole-3 acetic acid mitigates key hallmarks of metabolic dysfunction-associated steatotic liver disease (MASLD) in an NLRP3-dependent manner in in vitro and diet-induced mouse modelsPreprint
Sharma, P. K., Kumar, L., Baghel, A., Jana, P., Dhar, K., Bansal, R., Goswami, Y., Kumari, A., Yadav, R., Shalimar, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.25.701562 · Cited by 1
Gut Flora in the Development and Progression of Nonalcoholic Fatty Liver Disease
Okwu, V., & Matloob, A. (2015) · Journal of Liver Disease & Transplantation · doi:10.4172/2325-9612.1000128
Liver Cirrhosis with Steatohepatitis: Nonalcoholic Steatohepatitis and Alcoholic Steatohepatitis
Miyake, T., & Hiasa, Y. (2019) · Springer eBooks · doi:10.1007/978-981-13-7979-6_1
Role of extracellular vesicles in hypoxia-induced hepatic injury in non-alcoholic fatty liver disease
Villanueva, A. H. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.180853744
Interplays between nutritional and inflammatory signaling and fat metabolism in pathophysiology of NAFLD
Zheng, J., Chen, T., Guo, X., Ntambi, J. M., & Wu, C. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819404-1.00014-2
Effect of salvianolic acid B on NLRP3/caspase-1/GSDMD pyrolysis pathway in NASH cells
Chen, X.-Q., Peng, B., Jiang, H., Zhang, C.-X., Li, H., & Li, Z. (2022) · World Chinese Journal of Digestology · doi:10.11569/wcjd.v30.i2.69
Self-citation
NFATc1 driven ER-stress responses in the progression of non-alcoholic fatty liver disease
Latif, M. U. (2021) · doi:10.53846/goediss-8691
Peer Review #2 of "A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study (v0.1)"
(2022) · PeerJ · doi:10.7287/peerj.13022v0.1/reviews/2
Peer Review #3 of "A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study (v0.1)"
(2022) · PeerJ · doi:10.7287/peerj.13022v0.1/reviews/3
Peer Review #2 of "A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study (v0.2)"
(2022) · PeerJ · doi:10.7287/peerj.13022v0.2/reviews/2
Peer Review #3 of "A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study (v0.2)"
(2022) · PeerJ · doi:10.7287/peerj.13022v0.2/reviews/3
Peer Review #1 of "A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study (v0.1)"
(2022) · PeerJ · doi:10.7287/peerj.13022v0.1/reviews/1
Peer Review #1 of "A combined association of serum uric acid, alanine aminotransferase and waist circumference with non-alcoholic fatty liver disease: a community-based study (v0.2)"
(2022) · PeerJ · doi:10.7287/peerj.13022v0.2/reviews/1
Efecto del extracto hidroalcohólico de la planta Lampaya medicinalis Phil . sobre marcadores inflamación inducidos por ácidos grasos en hepatocitos humanos HepG2
Ormazabal, P., Yuri, G., Sanhueza, S., Cifuentes, M., Morales, G., & Paredes, A. (2022) · Revista chilena de nutrición · doi:10.4067/s0717-75182022000300344
From inflammation to fibrosis
Muriel, P. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99764-5.00010-x
Modulación de la microbiota intestinal en el tratamiento de la enfermedad de hígado graso no alcohólico y síndrome metabólico. Estudio de un tratamiento experimental con quercetina y de la transferencia de microbiota a ratones libres de gérmenes = Intestinal microbiota modulation in the treatment of non-alcoholic fatty liver disease and metabolic syndrome. Study of an experimental treatment with quercetin and intestinal microbiota transfer to germ-free mice
Porras, D. (2021) · Buleria (Universidad de León) · doi:10.18002/10612/13641
Inflammasome implications in metabolic disorders
Pellegrini, C., D’Antongiovanni, V., Benvenuti, L., Bernardini, N., Fornai, M., & Antonioli, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91802-2.00008-6
Bệnh gan nhiễm mỡ liên quan chuyển hóa (MAFLD): bệnh hệ thống ngoài gan
Minh, H. Đ. L., & Tuong, T. T. K. (2023) · Pham Ngoc Thach Journal of Medicine and Pharmacy · doi:10.59715/pntjmp.2.1.1
Toàn Văn Tập 2 Số 1 Năm 2023
dược, P. Y. (2023) · Pham Ngoc Thach Journal of Medicine and Pharmacy · doi:10.59715/pntjmp.2.1.0
The new epigenetic driver role of PPARα and mitochondria in metabolic dysfunction associated liver disease (MASLD), paving the way towards new therapeutics and diagnostic biomarkers
Theys, C. (2024) · doi:10.63028/10067/2022910151162165141
Exploring the Impacts of Polyethylene Microplastics on Rat LiverPreprint
Maurya, D., Katarkar, A., Kulurkar, P. M., Deshpande, S. A., Krishnamurthi, K., & Sivanesan, S. (2024) · Research Square · doi:10.21203/rs.3.rs-5196445/v1 · Cited by 1
NLRP1 is activated by palmitic acid and induced in human metabolic dysfunction-associated steatohepatitisPreprint
Pinilla, M., Baños, E. C., Martínez‐Sánchez, M. A., Sánchez‐Villalobos, M., Oliva‐Bolarín, A., Rico‐Chazarra, S., Ruiz‐Alcaraz, A. J., Martínez, C. M., Mika, A., Frutos, M. D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.11.622769
Additional file of Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity
Gao, Y., Xu, G., Ma, L., Shi, W., Wang, Z., Zhan, X., Qin, N., He, T., Guo, Y., Niu, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14432366
Additional file 1 of Dynamic co-expression modular network analysis in nonalcoholic fatty liver disease
Zheng, J., Wu, H., Zhang, Z., & Yao, S. (2021) · Figshare · doi:10.6084/m9.figshare.16305402
Additional file 1 of Association between serum uric acid levels and long-term mortality of metabolic dysfunction-associated fatty liver disease: a nationwide cohort study
Liu, Z., Wang, Q., Huang, H., Wang, X., & Xu, C. (2023) · Figshare · doi:10.6084/m9.figshare.22600945
Additional file 2 of Dynamic co-expression modular network analysis in nonalcoholic fatty liver disease
Zheng, J., Wu, H., Zhang, Z., & Yao, S. (2021) · Figshare · doi:10.6084/m9.figshare.16305405
Additional file 1 of Verapamil-loaded supramolecular hydrogel patch attenuates metabolic dysfunction-associated fatty liver disease via restoration of autophagic clearance of aggregated proteins and inhibition of NLRP3
Kim, D. K., Han, D., Bae, J., Kim, H., Lee, S., Kim, J.-S., Jeong, Y.-G., Shin, J., & Park, H.-W. (2023) · Figshare · doi:10.6084/m9.figshare.22605746
Additional file 1 of Red yeast rice ameliorates non-alcoholic fatty liver disease through inhibiting lipid synthesis and NF-κB/NLRP3 inflammasome-mediated hepatic inflammation in mice
Zou, J., Yan, C., & Wan, J.-B. (2022) · Figshare · doi:10.6084/m9.figshare.19069878
Additional file 2 of Icariside I specifically facilitates ATP or nigericin-induced NLRP3 inflammasome activation and causes idiosyncratic hepatotoxicity
Gao, Y., Xu, G., Ma, L., Shi, W., Wang, Z., Zhan, X., Qin, N., He, T., Guo, Y., Niu, M., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14432369
Body Roundness Index and All‐Cause Mortality in Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Dual‐Cohort Study
Li, Z., Yin, S., Cui, J., Shi, J., Ma, F., Ma, T., An, Q., Yu, T., Danian, T., Cao, X., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70685 · Cited by 1
Impact de la co-exposition au benzo[a]pyrène et à l'éthanol sur la progression pathologique de la stéatose hépatique
Tête, A. (2018) · theses.fr (ABES) · doi:10.70675/536d140cze42az4ee6zac88zf6315348b6fd
The roles of endoplasmic reticulum stress and Bax inhibitor-1 in non-alcoholic fatty liver disease
Lebeaupin, C. (2018) · theses.fr (ABES) · doi:10.70675/de500ab2z3c59z484dz8f58z7c3173626c42
Implication du microbiote intestinal humain dans l‘évolution des hépatopathies métaboliques non liées à l’alcoolisme (NAFLD)
Burz, S. D. (2020) · theses.fr (ABES) · doi:10.70675/0251c89dze5ccz4051z8852z69dd731e8d57
Rôle de LECT2 dans les maladies stéatosiques non alcooliques du foie
Pham, S. (2020) · theses.fr (ABES) · doi:10.70675/3693bfe6z9d91z4045za9a9zc37497dc9c1b
The functional role of Claudin-1 as a mediator and therapeutic target in liver fibrogenesis and hepatocarcinogenesis
Roehlen, N. (2021) · theses.fr (ABES) · doi:10.70675/f74abe25z2801z481cza9b8zb9232964c1fa
Tao-Hong-Si-Wu-Tang protects against methionine- and choline-deficient diet-induced hepatic steatosis in rats and is associated with inhibition of oxidative stress, inflammation, apoptosis, and pyroptosis
Luyao, X., Li, Q., Lu, C., Zheng, M., Guo, W., Chen, Y., Dai, J., Deng, Y., Zhang, N., Yang, K., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1767119
Self-citation
Microbiome‐Derived Metabolite Networks in Metabolic Dysfunction‐Associated Fatty Liver Disease: Mechanistic Integration of Gut‐Liver Axis Signaling and Therapeutic Targeting
Muniraj, A., Elango, S. V., Iyer, M., Rani, M. R., Vinayagam, S., Gnanasekaran, L., Yadav, M. K., Rao, K. R. S. S., Vellingiri, B., Mukherjee, A. G., et al. (2026) · Comprehensive physiology · doi:10.1002/cph4.70220 · Cited by 1
An Integrated Analysis to Understand the Dysregulation of Innate Immune Response in Mouse Models of MASLD
Goswami, Y., Gautam, J., Baghel, A., Kumari, D., Sharma, P. K., Priya, M. R. K., Bansal, R., Gulzar, F., Rk, Y., Aithal, G. P., et al. (2026) · Cells · doi:10.3390/cells15141298
The Hepatic Crown-like Structure: A Focal Point for Macrophage Evolution and Disease Response in Steatotic Liver Disease
Yuquimpo, K., Dare, A., Ruiz, I. A. P., & Weinman, S. A. (2026) · Livers · doi:10.3390/livers6040072
Targeting of NLRP3 Gln624/Ser658 by Carabrone attenuates inflammatory diseases
Jia, B., Abuduwaili, Z., Tang, H., Xiao, J., Zhang, R., Bao, X., Chen, J., Deng, S., Xu, Y., Yu, L., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179299
Targeting inflammasome in digestive diseases: A dual approach of Western and Chinese medicine
Qi, Q., Zhu, C.-H., Li, J.-L., & Yu, J. (2026) · World Journal of Gastroenterology · doi:10.3748/wjg.121899
The immunogenic cross-talk in pediatric MASLD: does subclinical immune dysfunction accelerate early hepatic destruction?
Mangge, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1930909

Authors: Wree, A., McGeough, M. D., Peña, C. A., Schlattjan, M., Li, H., Inzaugarat, M. E., Messer, K., Canbay, A., Hoffman, H. M., & Feldstein, A. E.
Affiliations: University of California San Diego (US)
Essen University Hospital (DE)
Corresponding author: Feldstein, Ariel E.
ORCID: Wree, Alexander
Schlattjan, Martin
Li, Hongying
Messer, Karen
Canbay, Ali
Hoffman, Hal M.
Feldstein, Ariel E.
Venue: Journal of Molecular Medicine
Publisher: Springer Science and Business Media LLC
Published: 2014-05-28
Volume: 92
Issue: 10
Pages: 1069-1082
ISSN: 0946-2716 (ISSN-L)
1432-1440
DOI: 10.1007/s00109-014-1170-1
PMC: PMC4349416
OpenAlex: W1977508200
Cited by: 486
References: 43
Citations by year: 2026: 18 · 2025: 31 · 2024: 31 · 2023: 64 · 2022: 66 · 2021: 63 · 2020: 69 · 2019: 27 · 2018: 37 · 2017: 33 · 2016: 27 · 2015: 17 · 2014: 3
FWCI: 20.20
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Journal of Molecular Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Americanae (AECID Library) (submittedVersion, cc-by-nc-sa)
eScholarship (California Digital Library) (submittedVersion)
LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
Funders: National Institute on Alcohol Abuse and Alcoholism (U01AA022489)
National Cancer Institute (P30CA023100)
National Institute of Allergy and Infectious Diseases (AI52430, R01AI052430)
National Institute of Diabetes and Digestive and Kidney Diseases (R01DK082451, R01DK076852, DK082451, DK-076852)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: NLRP3 inflammasome, non-alcoholic fatty liver disease, liver fibrosis, steatohepatitis, hepatic steatosis, NLRP3 knockout mice, pro-IL-1β, COL1A1, macrophage infiltration, liver inflammation, caspase-1
MeSH terms: NLR Family, Pyrin Domain-Containing 3 Protein, Collagen Type I, alpha 1 Chain, Animals, Carrier Proteins, Female, Fibrosis, Humans, Liver, Male, Mice, Transgenic, RNA, Messenger, Collagen Type I, Inflammasomes, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

NLRP3 inflammasome activation is required for fibrosis development in NAFLD

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks